These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19762694)

  • 21. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke.
    Ernst R; Pancioli A; Tomsick T; Kissela B; Woo D; Kanter D; Jauch E; Carrozzella J; Spilker J; Broderick J
    Stroke; 2000 Nov; 31(11):2552-7. PubMed ID: 11062274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous alteplase for stroke in those older than 80 years old.
    Ford GA; Ahmed N; Azevedo E; Grond M; Larrue V; Lindsberg PJ; Toni D; Wahlgren N
    Stroke; 2010 Nov; 41(11):2568-74. PubMed ID: 20930163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
    Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
    Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator.
    Schellinger PD; Chalela JA; Kang DW; Latour LL; Warach S
    AJNR Am J Neuroradiol; 2005 Mar; 26(3):618-24. PubMed ID: 15764589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
    Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
    Alvarez-Sabín J; Molina CA; Montaner J; Arenillas JF; Huertas R; Ribo M; Codina A; Quintana M
    Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry.
    Aoki J; Kimura K; Koga M; Kario K; Nakagawara J; Furui E; Shiokawa Y; Hasegawa Y; Okuda S; Yamagami H; Okada Y; Shibazaki K; Sakamoto Y; Toyoda K
    J Neurol Sci; 2013 Apr; 327(1-2):6-11. PubMed ID: 23433814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke.
    Koga M; Arihiro S; Miyashita F; Yamamoto H; Yamada N; Nagatsuka K; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2013; 36(4):299-305. PubMed ID: 24135558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Early Arterial Recanalization and Tissue Fate in the Selection of Patients With the Greatest Potential to Benefit From Intravenous Tissue-Type Plasminogen Activator.
    Leiva-Salinas C; Patrie JT; Xin W; Michel P; Jovin T; Wintermark M
    Stroke; 2016 Feb; 47(2):397-403. PubMed ID: 26696647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke.
    Qureshi AI; Ali Z; Suri MF; Kim SH; Shatla AA; Ringer AJ; Lopes DK; Guterman LR; Hopkins LN
    Neurosurgery; 2001 Jul; 49(1):41-8; discussion 48-50. PubMed ID: 11440458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion.
    Osaki M; Miyashita F; Koga M; Fukuda M; Shigehatake Y; Nagatsuka K; Minematsu K; Toyoda K
    Eur J Neurol; 2014 Mar; 21(3):411-8. PubMed ID: 24200315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.
    Saqqur M; Uchino K; Demchuk AM; Molina CA; Garami Z; Calleja S; Akhtar N; Orouk FO; Salam A; Shuaib A; Alexandrov AV;
    Stroke; 2007 Mar; 38(3):948-54. PubMed ID: 17290031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours.
    Deguchi I; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):1033-1040. PubMed ID: 29221968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset.
    Balogun IO; Brown A; Bertoni M; Webb T; Hargroves D; Pullicino P
    J Stroke Cerebrovasc Dis; 2016 Aug; 25(8):1843-50. PubMed ID: 27132489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Combination of Clinical Features, Transcranial Doppler, and Alberta Stroke Program Early Computed Tomography Score (Computed Tomography Angiography) in Predicting Outcome in Intravenous Recombinant Tissue Plasminogen Activator-Treated Patients.
    Saqqur M; Ghrooda E; Ahmad A; Khan K; Hussain MS; Shuaib A
    J Stroke Cerebrovasc Dis; 2016 Aug; 25(8):2019-23. PubMed ID: 27241578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator.
    Linfante I; Llinas RH; Selim M; Chaves C; Kumar S; Parker RA; Caplan LR; Schlaug G
    Stroke; 2002 Aug; 33(8):2066-71. PubMed ID: 12154264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.